BioWorld

June 27, 2007

Genentech, Abbott Partner To Develop Oncology Drugs

Genentech Inc. is acting the pharma part in a deal with Abbott to advance the latter's Phase I-stage compounds ABT-263 and ABT-869, a Bcl-2 protein antagonist and VEGF receptor kinase inhibitor, respectively. (BioWorld Today) Read More

MediciNova Picks 2 Programs, Looks To Partner Most Others

Broader Comparison Finds More Specific Angiogenesis Markers

NewCo News: Cequent's RNAi Platform Draws Novartis Investment, Option

Generex Gears Up For Phase III Trial Of Oral-lyn Insulin Spray

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

Illustration of head with maze that is missing parts

Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

BioWorld Science

Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...

VST Bio’s VB-001 is neuroprotector after stroke

BioWorld Science

At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...